好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Unilateral Motor Progression in Multiple Sclerosis: Association with a Single Critical Corticospinal Tract Lesion
Multiple Sclerosis
P5 - Poster Session 5 (5:30 PM-6:30 PM)
15-012

To determine if progressive unilateral motor impairment in multiple sclerosis (MS) patients with unlimited lesion burden can be attributable to a single critical demyelinating lesion.


Progressive motor impairment can be anatomically attributable to a single demyelinating lesion in “progressive solitary sclerosis” and MS patients with highly restricted central nervous system (CNS) lesion burden (≤5 lesions). These “critical lesions” are generally prominent, atrophic and located on specific corticospinal tract segments more susceptible to focal damage.


We included Mayo Clinic patients (1996-2017) with: (1) ≥1 year of exclusively unilateral motor progression; (2) >5 CNS demyelinating lesions; (3) MS diagnosis by 2017 McDonald criteria. A blinded neuroradiologist evaluated the last available brain and spinal cord MRI to identify a single potential critical lesion on the base of previously identified characteristics: (1) prominent size; (2) focal atrophy; (3) critical corticospinal tract location (spinal cord lateral column, medullary pyramid, cerebral peduncle or internal capsule).


Thirty-eight patients were included: primary progressive MS, 20 (53%); secondary progressive MS, 18 (47%). Median age at progression onset was 55 years (range, 39-73). Median EDSS was 5 (range, 2.5-7.5) at last follow-up (median, 120 months from symptom onset; range, 22-418). Progressive unilateral motor impairment was characterized by (face-sparing) hemiparesis or monoparesis. The neuroradiologist identified a potential critical lesion in 25 cases (66%): cervical cord, 19; thoracic cord, 6. In all, the progressive motor deficits were attributable to the selected lesion. The remaining 13 cases had ≥1 potential critical lesions; at least one for each patient was attributable to the motor deficit. The overall likelihood to find at least one demyelinating lesion along the corticospinal tract where the deficit localized was higher (100%) than on the contralateral side (39%) (p<0.0001).


In MS patients with unilateral motor progression, a single critical corticospinal tract lesion may be responsible.


Authors/Disclosures
Elia Sechi, MD (University of Sassari)
PRESENTER
Dr. Sechi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Sechi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx.
Mark Keegan, MD, FAAN (Mayo Clinic) Dr. Keegan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Keegan has received publishing royalties from a publication relating to health care. Dr. Keegan has received publishing royalties from a publication relating to health care.
No disclosure on file
Orhun H. Kantarci, MD Dr. Kantarci has nothing to disclose.
Brian G. Weinshenker, MD, FAAN (University of Virginia Health System) Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic) The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Merck. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology that is relevant to AAN interests or activities.